As discussions and the hype surrounding CRISPR’s (clustered regularly interspaced short palindromic repeats) potential applications increase, so do the legal and financial risks. Hailed as the biggest biological advancement since the polymerase chain reaction, the controversial, yet revolutionary, gene editing tool is now at the center of a major patent dispute over who owns the rights to exploit it commercially.
The battle, a testament to the high-stakes game of biotech investing, could make or break some businesses. With several startups looking to capitalize on the new method and some existing companies abandoning time-perfected techniques in favor of the cheaper, faster, easier option, this breakthrough technology has attracted hundreds of millions of dollars in investments and licensing deals.
Steve, Simon, and T.R. will be joined by Katherine Breedis, CFA, CMT, Managing Director and Senior Analyst – Major Pharmaceuticals & Biotechnology, Stifel Financial Corp. Together, they will analyze the key intellectual property complexities and investment risks surrounding this disruptive technology and offer tips for doing business in the space despite them.
Discussion topics will include:
Stephen B. Maebius, Partner and former Intellectual Property Department Chair, Foley & Lardner LLP
Katherine Breedis, CFA, CMT, Managing Director and Senior Analyst – Major Pharmaceuticals & Biotechnology, Stifel Financial Corp.
Simon J. Elliott, PhD, Senior Counsel, Foley & Lardner LLP
Tianran Yan, Senior Counsel, Foley & Lardner LLP
There is no cost to participate in this program but pre-registration is required. To participate, please use the Register Now button above or simply register here. Instructions for accessing the program will be included in the registration confirmation.
For more information, please contact Allison Jones at firstname.lastname@example.org.
|Navigating the CRISPR Patent Landscape and Business Impact is the first web conference in an ongoing Foley series entitled, Era-Defining Life Sciences Technologies. The series addresses the key intellectual property issues and business challenges of technology innovations – including those contributing to the discovery, development, and commercialization of regenerative and personalized medicines – that are disrupting the life sciences industry and creating new and uncertain opportunities.|